Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:BPMC

Blueprint Medicines (BPMC) Stock Price, News & Analysis

Blueprint Medicines logo

About Blueprint Medicines Stock (NASDAQ:BPMC)

Key Stats

Today's Range
$129.46
$129.46
50-Day Range
$127.95
$129.48
52-Week Range
$73.04
$129.65
Volume
N/A
Average Volume
1.55 million shs
Market Capitalization
$8.36 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$130.00
Consensus Rating
Hold

Company Overview

Blueprint Medicines Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
2nd Percentile Overall Score

BPMC MarketRank™: 

Blueprint Medicines scored higher than 2% of companies evaluated by MarketBeat, and ranked 958th out of 958 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Blueprint Medicines has received a consensus rating of Hold. The company's average rating score is 2.11, and is based on 2 buy ratings, 16 hold ratings, and no sell ratings.

  • Upside/Downside

    The consensus price target for Blueprint Medicines is close to its current price, suggesting limited near-term upside or downside.

  • Amount of Analyst Coverage

    Blueprint Medicines has received no research coverage in the past 90 days.

  • Read more about Blueprint Medicines' stock forecast and price target.
  • Earnings Growth

    Earnings for Blueprint Medicines are expected to grow in the coming year, from ($1.28) to $0.65 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Blueprint Medicines is -52.41, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Blueprint Medicines is -52.41, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Blueprint Medicines has a P/B Ratio of 27.54. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Blueprint Medicines' valuation and earnings.
  • Short Interest

    There is no current short interest data available for BPMC.
  • Dividend Yield

    Blueprint Medicines does not currently pay a dividend.

  • Dividend Growth

    Blueprint Medicines does not have a long track record of dividend growth.

  • Short Interest

    There is no current short interest data available for BPMC.
  • News Coverage This Week

    MarketBeat has tracked 1 news article for Blueprint Medicines this week, compared to 8 articles on an average week.
  • Search Interest

    2 people have searched for BPMC on MarketBeat in the last 30 days.
Receive BPMC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Blueprint Medicines and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

BPMC Stock News Headlines

Roche, Blueprint lung cancer drug wins FDA approval
Nvidia CEO Makes First Ever Tesla Announcement
While headlines focus on Tesla’s car sales, tech analyst Jeff Brown says the real story is Tesla’s role in a $25 trillion AI revolution — one that Nvidia’s CEO himself has called a “multi-trillion-dollar future industry” — and he’s uncovered a little-known stock 168 times smaller than Nvidia that could be positioned to ride this breakthrough.tc pixel
BPMC Blueprint Medicines Corporation - Seeking Alpha
Blueprint Medicines Corporation (BPMC) - Yahoo Finance
See More Headlines

BPMC Stock Analysis - Frequently Asked Questions

Blueprint Medicines Corporation (NASDAQ:BPMC) issued its earnings results on Thursday, May, 1st. The biotechnology company reported ($0.74) EPS for the quarter, missing the consensus estimate of ($0.42) by $0.32. The business's quarterly revenue was up 55.5% on a year-over-year basis.
Read the conference call transcript
.

Blueprint Medicines (BPMC) raised $115 million in an IPO on Thursday, April 30th 2015. The company issued 7,200,000 shares at $15.00-$17.00 per share. Goldman Sachs and Cowen and Company served as the underwriters for the IPO and JMP Securities and Wedbush PacGrow were co-managers.

Based on aggregate information from My MarketBeat watchlists, some other companies that Blueprint Medicines investors own include American Water Works (AWK), Voyager Therapeutics (VYGR), Waste Connections (WCN), The RMR Group (RMR), Humana (HUM), DiamondRock Hospitality (DRH) and AUO (AUOTY).

Company Calendar

Last Earnings
5/01/2025
Today
10/10/2025
Next Earnings (Estimated)
10/28/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:BPMC
CIK
1597264
Fax
N/A
Employees
640
Year Founded
2011

Price Target and Rating

High Price Target
$135.00
Low Price Target
$119.00
Potential Upside/Downside
+0.4%
Consensus Rating
Hold
Rating Score (0-4)
2.11
Research Coverage
18 Analysts

Profitability

EPS (Trailing Twelve Months)
($2.47)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$67.09 million
Net Margins
-27.70%
Pretax Margin
-27.38%
Return on Equity
-64.60%
Return on Assets
-17.22%

Debt

Debt-to-Equity Ratio
1.01
Current Ratio
2.80
Quick Ratio
2.75

Sales & Book Value

Annual Sales
$562.12 million
Price / Sales
14.87
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$4.70 per share
Price / Book
27.54

Miscellaneous

Outstanding Shares
64,582,000
Free Float
61,863,000
Market Cap
$8.36 billion
Optionable
Optionable
Beta
0.89

Social Links

Beginner's Guide To Retirement Stocks Cover

Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

This page (NASDAQ:BPMC) was last updated on 10/10/2025 by MarketBeat.com Staff
From Our Partners